Albumin-Bound Paclitaxel plus Gemcitabine in Pancreatic Cancer

被引：61

作者：

Saltz, Leonard B. ^{[1
]}

Bach, Peter B. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2014年 / 370卷 / 05期

关键词：

D O I：

10.1056/NEJMc1314761

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

To the Editor: The article by Von Hoff et al. (Oct. 31 issue)(1) is entitled Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. This title strikes us as inappropriately rosy, given the modest benefits and substantial toxic effects observed. The addition of nab-paclitaxel increased the median survival by 1.8 months, or 55 days. The chance of being alive at 2 years was increased from 4% to 9%. Meanwhile, an additional 10% of patients had grade 3 (severe) fatigue. Grade 2 fatigue (moderate, not relieved by rest) and duration of fatigue are not mentioned. Grade 3 (severe) neuropathy was increased ...

引用

页码：478 / 478

页数：1

共 50 条

[41] Exceptional Response to Nanoparticle Albumin-Bound Paclitaxel and Gemcitabine in a Patient with a Refractory Adenocarcinoma of the Ampulla of Vater
Kapp, Markus
Kosmala, Aleksander
Kircher, Stefan
Luber, Verena
Kunzmann, Volker
CASE REPORTS IN ONCOLOGY, 2016, 9 (01): : 15 - 24
[42] Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies
Stinchcombe, Thomas E.
Socinski, Mark A.
Lee, Carrie B.
Hayes, D. Neil
Moore, Dominic T.
Goldberg, Richard M.
Dees, E. Claire
JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (05) : 521 - 526
[43] Efficacy of gemcitabine in combination with nanoparticle albumin-bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review
Kase, Adam M.
Azzouqa, Abdel-Ghani
Kochuveettil, Swapna
Colon-Otero, Gerardo
CANCER MEDICINE, 2023, 12 (08): : 9434 - 9438
[44] Induction chemotherapy with albumin-bound paclitaxel plus lobaplatin followed by concurrent radiochemotherapy for locally advanced esophageal cancer
Yan, Mao-Hui
Liu, Fang
Qu, Bao-Lin
Cai, Bo-Ning
Yu, Wei
Dai, Xiang-Kun
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 13 (11) : 1781 - 1790
[45] Induction chemotherapy with albumin-bound paclitaxel plus lobaplatin followed by concurrent radiochemotherapy for locally advanced esophageal cancer
Mao-Hui Yan
Fang Liu
Bao-Lin Qu
Bo-Ning Cai
Wei Yu
Xiang-Kun Dai
World Journal of Gastrointestinal Oncology, 2021, (11) : 1781 - 1790
[46] Neoadjuvant therapy with nanoparticle albumin-bound (nab)-paclitaxel to enhance the resectability of locally advanced pancreatic cancer (LAPC)
Cooray, Prasad
Dean, Andrew Peter
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[47] Albumin-Bound Paclitaxel: A Review of Its Use for the First-Line Combination Treatment of Metastatic Pancreatic Cancer
Sheridan M. Hoy
Drugs, 2014, 74 : 1757 - 1768
[48] Evaluation of the efficacy and safety of FOLFIRINOX or albumin-bound paclitaxel in combination with S-1 in patients with pancreatic cancer
Li, Luan
Feng, Yuxu
Li, Chenchen
Liu, Siwen
Yan, Fei
Zhu, Jingni
Li, Xiaoyou
Li, Sheng
International Journal of Industrial Chemistry, 2022, 13 (01) : 12 - 19
[49] Albumin-Bound Paclitaxel: A Review of Its Use for the First-Line Combination Treatment of Metastatic Pancreatic Cancer
Hoy, Sheridan M.
DRUGS, 2014, 74 (15) : 1757 - 1768
[50] Risk comparison of adverse reactions between gemcitabine monotherapy and gemcitabine combined with albumin-bound paclitaxel in pancreatic cancer: insights from the FDA Adverse Event Reporting System (FAERS) database
Jiang, Puen
Zong, Kezhen
Peng, Dadi
Zhou, Baoyong
Wu, Zhongjun
BMC PHARMACOLOGY & TOXICOLOGY, 2025, 26 (01):

← 1 2 3 4 5 →